Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.

@article{Schraa2002TargetingOR,
  title={Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.},
  author={Astrid J Schraa and Robbert Jan Kok and Henk E. Moorlag and Erwin J Bos and Johannes H Proost and Dirk K. F. Meijer and Lou F. M. H. de Leij and Grietje Molema},
  journal={International journal of cancer},
  year={2002},
  volume={102 5},
  pages={469-75}
}
Angiogenesis-associated integrin alpha(v)beta(3) represents an attractive target for therapeutic intervention because it becomes highly upregulated on angiogenic endothelium and plays an important role in the survival of endothelial cells. Cyclic RGD peptides were prior shown to have a high affinity for alpha(v)beta(3) and can induce apoptosis of endothelial cells. In our laboratory, monocyclic RGD peptides (cRGDfK) were chemically coupled to a protein backbone. Previous results demonstrated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.

Journal of controlled release : official journal of the Controlled Release Society • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…